Recursion Pharmaceuticals Statistics

Total Valuation

RXRX has a market cap or net worth of $1.85 billion. The enterprise value is $1.48 billion.

Market Cap	1.85B
Enterprise Value	1.48B

Important Dates

The next confirmed earnings date is Wednesday, November 6, 2024, after market close.

Earnings Date	Nov 6, 2024
Ex-Dividend Date	n/a

Share Statistics

RXRX has 280.97 million shares outstanding. The number of shares has increased by 20.41% in one year.

Current Share Class	273.61M
Shares Outstanding	280.97M
Shares Change (YoY)	+20.41%
Shares Change (QoQ)	+2.62%
Owned by Insiders (%)	6.73%
Owned by Institutions (%)	91.23%
Float	246.43M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	30.49
Forward PS	24.17
PB Ratio	3.19
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	29.84
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 6.07, with a Debt / Equity ratio of 0.15.

Current Ratio	6.07
Quick Ratio	5.54
Debt / Equity	0.15
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-850.70

Financial Efficiency

Return on equity (ROE) is -71.18% and return on invested capital (ROIC) is -41.43%.

Return on Equity (ROE)	-71.18%
Return on Assets (ROA)	-34.35%
Return on Capital (ROIC)	-41.43%
Revenue Per Employee	$99,270
Profits Per Employee	-$749,852
Employee Count	500
Asset Turnover	0.07
Inventory Turnover	n/a

Taxes

Income Tax	-5.36M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +12.35% in the last 52 weeks. The beta is 0.80, so RXRX's price volatility has been lower than the market average.

Beta (5Y)	0.80
52-Week Price Change	+12.35%
50-Day Moving Average	6.62
200-Day Moving Average	8.53
Relative Strength Index (RSI)	51.01
Average Volume (20 Days)	3,986,665

Short Selling Information

The latest short interest is 59.44 million, so 21.15% of the outstanding shares have been sold short.

Short Interest	59.44M
Short Previous Month	62.58M
Short % of Shares Out	21.15%
Short % of Float	24.12%
Short Ratio (days to cover)	11.89

Income Statement

In the last 12 months, RXRX had revenue of $49.64 million and -$374.93 million in losses. Loss per share was -$1.64.

Revenue	49.64M
Gross Profit	-272.47M
Operating Income	-396.42M
Pretax Income	-380.29M
Net Income	-374.93M
EBITDA	-364.95M
EBIT	-396.42M
Loss Per Share	-$1.64

Full Income Statement

Balance Sheet

The company has $474.34 million in cash and $89.88 million in debt, giving a net cash position of $384.47 million or $1.37 per share.

Cash & Cash Equivalents	474.34M
Total Debt	89.88M
Net Cash	384.47M
Net Cash Per Share	$1.37
Equity (Book Value)	584.45M
Book Value Per Share	2.08
Working Capital	436.29M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$331.52 million and capital expenditures -$10.65 million, giving a free cash flow of -$342.16 million.

Operating Cash Flow	-331.52M
Capital Expenditures	-10.65M
Free Cash Flow	-342.16M
FCF Per Share	-$1.22

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-798.68%
Pretax Margin	-766.17%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	-689.36%

Dividends & Yields

RXRX does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-20.41%
Shareholder Yield	-20.41%
Earnings Yield	-20.10%
FCF Yield	-18.34%

Dividend Details

Analyst Forecast

The average price target for RXRX is $9.40, which is 42.86% higher than the current price. The consensus rating is "Buy".

Price Target	$9.40
Price Target Difference	42.86%
Analyst Consensus	Buy
Analyst Count	6
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

RXRX has an Altman Z-Score of 3.33 and a Piotroski F-Score of 2.

Altman Z-Score	3.33
Piotroski F-Score	2